Age-related decline in murine heart and skeletal muscle performance is attenuated by reduced Ahnak1 expression.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
10 2021
Historique:
revised: 13 05 2021
received: 08 01 2021
accepted: 08 06 2021
pubmed: 3 7 2021
medline: 26 11 2021
entrez: 2 7 2021
Statut: ppublish

Résumé

Aging is associated with a progressive reduction in cellular function leading to poor health and loss of physical performance. Mitochondrial dysfunction is one of the hallmarks of aging; hence, interventions targeting mitochondrial dysfunction have the potential to provide preventive and therapeutic benefits to elderly individuals. Meta-analyses of age-related gene expression profiles showed that the expression of Ahnak1, a protein regulating several signal-transduction pathways including metabolic homeostasis, is increased with age, which is associated with low VO We employed 15- to 16-month-old female and male Ahnak1-knockout (Ahnak1-KO) and wild-type (WT) mice and performed morphometric, biochemical, and bioenergetics assays to evaluate the effects of Ahnak1 on exercise capacity and mitochondrial morphology and function in cardiomyocytes and tibialis anterior (TA) muscle. A human left ventricular (LV) cardiomyocyte cell line (AC16) was used to investigate the direct role of Ahnak1 in cardiomyocytes. We found that the level of Ahnak1 protein is significantly up-regulated with age in the murine LV (1.9-fold) and TA (1.8-fold) tissues. The suppression of Ahnak1 was associated with improved exercise tolerance, as all aged adult Ahnak1-KO mice (100%) successfully completed the running programme, whereas approximately 31% male and 8% female WT mice could maintain the required running speed and distance. Transmission electron microscopic studies showed that LV and TA tissue specimens of aged adult Ahnak1-KO of both sexes have significantly more enlarged/elongated mitochondria and less small mitochondria compared with WT littermates (P < 0.01 and P < 0.001, respectively) at basal level. Further, we observed a shift in mitochondrial fission/fusion balance towards fusion in cardiomyocytes and TA muscle from aged adult Ahnak1-KO mice. The maximal and reserve respiratory capacities were significantly higher in cardiomyocytes from aged adult Ahnak1-KO mice compared with the WT counterparts (P < 0.05 and P < 0.01, respectively). Cardiomyocyte contractility and fatigue resistance of TA muscles were significantly increased in Ahnak1-KO mice of both sexes, compared with the WT groups. In vitro studies using AC16 cells have confirmed that the alteration of mitochondrial function is indeed a direct effect of Ahnak1. Finally, we presented Ahnak1 as a novel cardiac mitochondrial membrane-associated protein. Our data suggest that Ahnak1 is involved in age-related cardiac and skeletal muscle dysfunction and could therefore serve as a promising therapeutical target.

Sections du résumé

BACKGROUND
Aging is associated with a progressive reduction in cellular function leading to poor health and loss of physical performance. Mitochondrial dysfunction is one of the hallmarks of aging; hence, interventions targeting mitochondrial dysfunction have the potential to provide preventive and therapeutic benefits to elderly individuals. Meta-analyses of age-related gene expression profiles showed that the expression of Ahnak1, a protein regulating several signal-transduction pathways including metabolic homeostasis, is increased with age, which is associated with low VO
METHODS
We employed 15- to 16-month-old female and male Ahnak1-knockout (Ahnak1-KO) and wild-type (WT) mice and performed morphometric, biochemical, and bioenergetics assays to evaluate the effects of Ahnak1 on exercise capacity and mitochondrial morphology and function in cardiomyocytes and tibialis anterior (TA) muscle. A human left ventricular (LV) cardiomyocyte cell line (AC16) was used to investigate the direct role of Ahnak1 in cardiomyocytes.
RESULTS
We found that the level of Ahnak1 protein is significantly up-regulated with age in the murine LV (1.9-fold) and TA (1.8-fold) tissues. The suppression of Ahnak1 was associated with improved exercise tolerance, as all aged adult Ahnak1-KO mice (100%) successfully completed the running programme, whereas approximately 31% male and 8% female WT mice could maintain the required running speed and distance. Transmission electron microscopic studies showed that LV and TA tissue specimens of aged adult Ahnak1-KO of both sexes have significantly more enlarged/elongated mitochondria and less small mitochondria compared with WT littermates (P < 0.01 and P < 0.001, respectively) at basal level. Further, we observed a shift in mitochondrial fission/fusion balance towards fusion in cardiomyocytes and TA muscle from aged adult Ahnak1-KO mice. The maximal and reserve respiratory capacities were significantly higher in cardiomyocytes from aged adult Ahnak1-KO mice compared with the WT counterparts (P < 0.05 and P < 0.01, respectively). Cardiomyocyte contractility and fatigue resistance of TA muscles were significantly increased in Ahnak1-KO mice of both sexes, compared with the WT groups. In vitro studies using AC16 cells have confirmed that the alteration of mitochondrial function is indeed a direct effect of Ahnak1. Finally, we presented Ahnak1 as a novel cardiac mitochondrial membrane-associated protein.
CONCLUSIONS
Our data suggest that Ahnak1 is involved in age-related cardiac and skeletal muscle dysfunction and could therefore serve as a promising therapeutical target.

Identifiants

pubmed: 34212535
doi: 10.1002/jcsm.12749
pmc: PMC8517348
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1249-1265

Informations de copyright

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Circ Res. 2011 Dec 9;109(12):1327-31
pubmed: 22052916
Eur Heart J. 2013 Feb;34(7):512-9
pubmed: 23178647
Int J Cardiol. 2016 Nov 1;222:41-46
pubmed: 27454614
Bioinformatics. 2009 Apr 1;25(7):875-81
pubmed: 19189975
Curr Opin Genet Dev. 2016 Jun;38:38-44
pubmed: 27061490
Cardiovasc Res. 2011 Jun 1;90(3):513-20
pubmed: 21262909
FASEB J. 2005 Mar;19(3):419-21
pubmed: 15642720
Circulation. 2010 May 11;121(18):2012-22
pubmed: 20421521
Yeast. 1996 Mar 30;12(4):333-48
pubmed: 8701606
Biochim Biophys Acta. 2013 Jan;1833(1):205-12
pubmed: 22406072
BMJ. 2018 May 8;361:k1651
pubmed: 29739772
Aging (Albany NY). 2018 Nov 18;10(11):3327-3352
pubmed: 30449736
EMBO J. 2020 Feb 3;39(3):e102817
pubmed: 31912925
Physiol Rev. 2009 Jul;89(3):799-845
pubmed: 19584314
J Gerontol A Biol Sci Med Sci. 2018 Apr 17;73(5):608-616
pubmed: 28958065
Front Med (Lausanne). 2018 Mar 12;5:61
pubmed: 29662881
Circ Res. 2012 Apr 13;110(8):1109-24
pubmed: 22499901
Am J Physiol Endocrinol Metab. 2015 Aug 1;309(3):E224-32
pubmed: 26037248
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Basic Res Cardiol. 2017 Jan;112(1):1
pubmed: 27837311
J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):349-369
pubmed: 28432755
BMJ. 2015 Jan 21;350:h100
pubmed: 25608694
Exp Gerontol. 2017 Oct 1;96:1-6
pubmed: 28577890
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4053-8
pubmed: 15007166
Biochim Biophys Acta Mol Basis Dis. 2020 Nov 1;1866(11):165899
pubmed: 32698045
J Cell Mol Med. 2020 May;24(9):4892-4899
pubmed: 32279443
Biomed Res Int. 2015;2015:462592
pubmed: 26550569
J Mol Cell Cardiol. 2001 Jan;33(1):37-47
pubmed: 11133221
Skelet Muscle. 2015 Oct 09;5:35
pubmed: 26457177
Oncotarget. 2015 Jul 20;6(20):17923-37
pubmed: 26053100
PLoS Genet. 2006 Jul;2(7):e115
pubmed: 16789832
Nat Protoc. 2007;2(10):2480-91
pubmed: 17947990
Cytoskeleton (Hoboken). 2020 Mar;77(3-4):149-166
pubmed: 31479585
FASEB J. 2004 May;18(7):839-41
pubmed: 15001564
J Cell Sci. 2018 Sep 10;131(17):
pubmed: 30111583
EMBO Mol Med. 2015 Apr 10;7(7):865-77
pubmed: 25861797
Clin Interv Aging. 2016 Nov 09;11:1579-1587
pubmed: 27877027
J Mol Cell Cardiol. 2005 Jul;39(1):133-47
pubmed: 15913645
J Cell Sci. 1978 Dec;34:65-79
pubmed: 748347
Cardiovasc Res. 2008 Jul 15;79(2):208-17
pubmed: 18430751
FASEB J. 2005 Jan;19(1):43-52
pubmed: 15629894
Aging Cell. 2008 Jan;7(1):2-12
pubmed: 18028258
Biochim Biophys Acta. 2015 Nov;1847(11):1424-33
pubmed: 26191650
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Cell Signal. 2014 Dec;26(12):2683-93
pubmed: 25172424
Bioessays. 2015 Jun;37(6):687-700
pubmed: 25847815
Curr Biol. 2009 Dec 15;19(23):2008-13
pubmed: 19932026
Mol Cell Biol. 2012 Jan;32(2):309-19
pubmed: 22083962
Biochemistry (Mosc). 2015 May;80(5):604-9
pubmed: 26071780
J Exp Med. 2018 Jan 2;215(1):303-318
pubmed: 29203538
Exp Gerontol. 2013 Mar;48(3):341-8
pubmed: 23337778
Chem Biol Interact. 2011 May 30;191(1-3):288-95
pubmed: 21147079
J Aging Res. 2012;2012:192503
pubmed: 22720157
Pflugers Arch. 2020 Feb;472(2):179-193
pubmed: 32048000
Biomed Res Int. 2018 Jun 10;2018:7156435
pubmed: 29984246
Cell Metab. 2015 Feb 3;21(2):195-205
pubmed: 25651174
Am J Physiol Endocrinol Metab. 2008 Jun;294(6):E1152-9
pubmed: 18445752
Cardiovasc Res. 2012 Dec 1;96(3):411-21
pubmed: 22962310
J Biol Chem. 2009 Sep 11;284(37):24705-14
pubmed: 19584059
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1249-1265
pubmed: 34212535
EMBO J. 2010 May 19;29(10):1774-85
pubmed: 20400940
Oxid Med Cell Longev. 2017;2017:2012798
pubmed: 28900532
Biogerontology. 2008 Apr;9(2):67-84
pubmed: 18175203

Auteurs

Shokoufeh Mahmoodzadeh (S)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.

Katharina Koch (K)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Cindy Schriever (C)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Jingman Xu (J)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Heart Institute, School of Public Health, North China University of Science and Technology, Tangshan, China.

Maria Steinecker (M)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Joachim Leber (J)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Elke Dworatzek (E)

DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, and Berliner Institute of Health, Berlin, Germany.

Bettina Purfürst (B)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Severine Kunz (S)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Deborah Recchia (D)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Monica Canepari (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Arnd Heuser (A)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Silvia Di Francescantonio (S)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Experimental and Clinical Research Center, Charité-Universitaetsmedizin Berlin, Berlin, Germany.

Ingo Morano (I)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH